The p53-MDM2/MDMX axis - A chemotype perspective

被引:58
作者
Khoury, Kareem [1 ]
Popowicz, Grzegorz M. [2 ]
Holak, Tad A. [2 ]
Doemling, Alexander [1 ]
机构
[1] Univ Pittsburgh, Dept Pharmaceut Sci, Drug Discovery Inst, Pittsburgh, PA 15260 USA
[2] Max Planck Inst Biochem, D-8000 Munich, Germany
关键词
PROTEIN-PROTEIN INTERACTION; SUPPRESSOR TRANSACTIVATION DOMAIN; SMALL-MOLECULE ANTAGONISTS; STRUCTURE-BASED DESIGN; WILD-TYPE P53; MDM2; INHIBITORS; CANCER-THERAPY; IN-VIVO; IDENTIFY DISRUPTORS; HDM2; ANTAGONISTS;
D O I
10.1039/c0md00248h
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The protein-protein interaction (PPI) of the tumor suppressor p53 and its negative regulator MDM2 consists of the most intense studied PPI with a group of small molecular weight antagonists described and many more disclosed in patent literature. Due to the A-level structural insight into p53 interaction with MDM2 there is a reasonable understanding of the requirements of the molecules to bind. In contrast and despite the very close homology and 3-D similarity no potent MDMX antagonist has been disclosed up to date. The current review summarizes the different disclosed chemotypes for MDM2 including a discussion of the cocrystal structures. Structures and approaches to reconstitute functional p53 from mutated p53 are presented. Finally new screening methods and recent biotech deals based on p53 are discussed.
引用
收藏
页码:246 / 260
页数:15
相关论文
共 50 条
  • [1] p53-MDM2 and MDMX Antagonists
    Neochoritis, Constantinos
    Estrada-Ortiz, Natalia
    Khoury, Kareem
    Domling, Alexander
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 167 - 187
  • [2] Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction
    Lemos, Agostinho
    Leao, Mariana
    Soares, Joana
    Palmeira, Andreia
    Pinto, Madalena
    Saraiva, Lucilia
    Sousa, Maria Emilia
    MEDICINAL RESEARCH REVIEWS, 2016, 36 (05) : 789 - 844
  • [3] Systematic Mutational Analysis of Peptide Inhibition of the p53-MDM2/MDMX Interactions
    Li, Chong
    Pazgier, Marzena
    Li, Changqing
    Yuan, Weirong
    Liu, Min
    Wei, Gang
    Lu, Wei-Yue
    Lu, Wuyuan
    JOURNAL OF MOLECULAR BIOLOGY, 2010, 398 (02) : 200 - 213
  • [4] Recent Advances of p53-MDM2 Small Molecule Inhibitors (2011-Present)
    Lv, Peng-Cheng
    Sun, Juan
    Zhu, Hai-Liang
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (05) : 618 - 626
  • [5] Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition
    Madden, Michael M.
    Muppidi, Avinash
    Li, Zhenyu
    Li, Xiaolong
    Chen, Jiandong
    Lin, Qing
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1472 - 1475
  • [6] Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions
    Barakat, Khaled
    Mane, Jonathan
    Friesen, Douglas
    Tuszynski, Jack
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2010, 28 (06) : 555 - 568
  • [7] Small-Molecule Inhibitors of the p53-MDM2 Interaction
    Vu, Binh T.
    Vassilev, Lyubomir
    SMALL-MOLECULE INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS, 2011, 348 : 151 - 172
  • [8] Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX
    Wang, Yali
    Ji, Bo
    Cheng, Zhongshui
    Zhang, Lianghui
    Cheng, Yingying
    Li, Yingying
    Ren, Jin
    Liu, Wenbo
    Ma, Yuanyuan
    MOLECULES, 2022, 27 (12):
  • [9] Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors
    Su, Aoze
    Tabata, Yuko
    Aoki, Kiyono
    Sada, Akane
    Ohki, Rieko
    Nagatoishi, Satoru
    Tsumoto, Kouhei
    Wang, Siyuan
    Otani, Yuko
    Ohwada, Tomohiko
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2021, 69 (07) : 681 - 692
  • [10] Artificial Macrocycles as Potent p53-MDM2 Inhibitors
    Estrada-Ortiz, Natalia
    Neochoritis, Constantinos G.
    Twarda-Clapa, Aleksandra
    Musielak, Bogdan
    Holak, Tad A.
    Domling, Alexander
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (10): : 1025 - 1030